Novartis AG (NOVN.SW)
| Previous close | 88.10 |
| Open | 88.26 |
| Bid | 89.56 x 0 |
| Ask | 89.57 x 0 |
| Day's range | 88.07 - 89.81 |
| 52-week range | 79.21 - 94.52 |
| Volume | |
| Avg. volume | 3,233,072 |
| Market cap | 182.78B |
| Beta (5Y monthly) | 0.47 |
| PE ratio (TTM) | 22.51 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 3.30 (3.75%) |
| Ex-dividend date | 07 Mar 2024 |
| 1y target est | N/A |
- GlobeNewswire
Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update
– Continued enrollment globally in multiple clinical studies of vepdegestrant in ER+/HER2- metastatic breast cancer, including the VERITAC-2 Phase 3 trial in the second-line setting and the study lead-in for the VERITAC-3 Phase 3 trial in the first-line setting – – Top-line data readout for VERITAC-2 remains on-track for 2H 2024 – – Entered a transaction with Novartis providing an exclusive license for ARV-766 and sale of preclinical AR-V7 program; $150 million upfront payment and potential for
- GlobeNewswire
Novartis and Medicines for Malaria Venture announce positive efficacy and safety data for a novel treatment for babies <5 kg with malaria
There is currently no evidence-based treatment for the smallest babies with malaria The CALINA study tested a new ratio and dose of Coartem® (artemether- lumefantrine) to account for metabolic differences in babies under 5 kg The CALINA trial indicated that the new formulation has good efficacy and safety, and the data have been submitted for regulatory review Basel, April 24, 2024 – Novartis and Medicines for Malaria Venture (MMV) announce positive data from their phase II/III CALINA study, dem
- Globe Newswire
Novartis radioligand therapy Lutathera® FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors
Approval based on NETTER-P trial in which Lutathera demonstrated a consistent safety profile and comparable drug exposure between pediatric (ages 12-17) and adult patients Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are a rare cancer that is often unresectable and commonly diagnosed in the late stages of diseaseNovartis, a leader in radioligand therapy (RLT), is investigating a portfolio of RLTs to treat a broad range of cancers, including GEP-NETs, lung, prostate, breast, colon, bra
